Technical Analysis for KPTI - Karyopharm Therapeutics Inc.

Grade Last Price % Change Price Change
grade B 11.32 -3.33% -0.39
KPTI closed down 3.33 percent on Thursday, September 19, 2019, on 85 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical KPTI trend table...

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Boomer Buy Setup Bullish Swing Setup -3.33%
Upper Bollinger Band Walk Strength -3.33%
Wide Bands Range Expansion -3.33%
Overbought Stochastic Strength -3.33%
Jack-in-the-Box Bullish Bullish Swing Setup -3.00%

Older signals for KPTI ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The company's lead drug candidate includes Selinexor, an oral selective inhibitors of nuclear export (SINE) compound that specifically blocks XPO1 cargo binding is in Phase I clinical trials in patients with heavily pretreated relapsed and/or refractory hematological and solid tumor malignancies. Its other drug candidates comprise KPT-350 and related SINE compounds; PAK4 inhibitors; and Verdinexor, a SINE compound that is in Phase IIb clinical trials in pet dogs with newly-diagnosed or first relapse after chemotherapy lymphomas. The company was founded in 2008 and is based in Natick, Massachusetts.
Medicine Cancer Pharmaceutical Diseases Treatment Of Cancer Oncology Chemotherapy Occupational Safety And Health Antibody Drug Conjugates Pixantrone
Is KPTI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Sep 19 The Gross Law Firm Announces Class Actions on Behalf of Shareholders of KPTI, EGBN and TXT
Sep 19 KPTI DEADLINE: Pawar Law Group Reminds Investors of September 23 Deadline in Securities Class Action Lawsuit Against Karyopharm Therapeutics Inc. - KPTI
Sep 19 FINAL DEADLINE ALERT - Karyopharm Therapeutics Inc. (KPTI) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders With Losses Exceeding $100K of Class Action and Lead Deadline: September 23, 2019
Sep 19 SHAREHOLDER ALERT: LB KPTI EGBN MDP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
Sep 19 CLASS ACTION DEADLINE UPDATE: Brodsky & Smith, LLC Reminds Investors of Looming Deadlines For Securities Violations: LB and KPTI
Sep 19 SHAREHOLDER ALERT: KPTI NGHC MNK: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
Sep 19 DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Karyopharm Therapeutics, Inc. (NASDAQ: KPTI) and Encourages Karyopharm Investors to Contact the Firm
Sep 18 The Gross Law Firm Announces Class Actions on Behalf of Shareholders of LB, KPTI and GTT
Sep 18 UPCOMING DEADLINE ALERT - Karyopharm Therapeutics Inc. (KPTI) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders With Losses Exceeding $100K of Class Action and Lead Deadline: September 23, 2019
Sep 18 The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of KPTI, GTT and CAH
See more KPTI news...
Indicators
Indicator Value
52 Week High 19.19
52 Week Low 3.92
Average Volume 1,593,590
200-Day Moving Average 7.3864
50-Day Moving Average 9.0794
20-Day Moving Average 9.8065
10-Day Moving Average 10.814
Average True Range 0.6374
ADX 34.21
+DI 33.6673
-DI 10.1327
Chandelier Exit (Long, 3 ATRs ) 10.4278
Chandelier Exit (Short, 3 ATRs ) 9.9322
Upper Bollinger Band 12.1588
Lower Bollinger Band 7.4542
Percent B (%b) 0.82
BandWidth 47.974303
MACD Line 0.7778
MACD Signal Line 0.5757
MACD Histogram 0.202
Fundamentals Value
Market Cap 533.6 Million
Num Shares 47.1 Million
EPS -2.69
Price-to-Earnings (P/E) Ratio -4.21
Price-to-Sales 2836.82
Price-to-Book 2.82
PEG Ratio -0.13
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.28
Resistance 3 (R3) 12.35 12.09 12.12
Resistance 2 (R2) 12.09 11.85 12.06 12.07
Resistance 1 (R1) 11.71 11.70 11.58 11.64 12.01
Pivot Point 11.45 11.45 11.39 11.42 11.45
Support 1 (S1) 11.07 11.21 10.94 11.00 10.63
Support 2 (S2) 10.81 11.06 10.78 10.57
Support 3 (S3) 10.43 10.81 10.52
Support 4 (S4) 10.36